Trials / Withdrawn
WithdrawnNCT05147415
Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)
A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose-finding, Multi-center, 36-week Safety and Efficacy Study With Open-label Extension (OLE) Period of Tesomet in Subjects With Hypothalamic Obesity
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Saniona · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of Tesomet (tesofensine + metoprolol) in subjects 18 years of age or older, with HO
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Placebo | Inactive comparator |
| DRUG | Tesomet | Fixed-dose combination |
Timeline
- Start date
- 2021-11-11
- Primary completion
- 2022-12-09
- Completion
- 2022-12-09
- First posted
- 2021-12-07
- Last updated
- 2022-12-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05147415. Inclusion in this directory is not an endorsement.